Expert Review of Pharmacoeconomics & Outcomes Research

Papers
(The TQCC of Expert Review of Pharmacoeconomics & Outcomes Research is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Engagement of medication users in the development and implementation of digital medication adherence technologies: a multi-stakeholder study30
Indication-based pricing of the pharmaceuticals in Croatia: case-study23
Clinical and economic impact analysis of viscosupplementation with hylan G-F 20 versus hyaluronic acids and no viscosupplementation for the treatment of knee osteoarthritis in Colombia21
How to create value with constrained budgets in oncological care? A narrative review18
Direct medical and indirect absenteeism costs among working adult ADHD patients in the United States17
Economic value of knowing BRCA status: BRCA testing for prostate cancer prevention and optimal treatment16
Adherence to augmentation therapy for the treatment of major depressive disorder16
Social care data in the UK; current landscape, challenges, and future recommendations16
The impact of changing the funding model for genetic diagnostics and improved access to personalized medicine in oncology15
Time from approval to reimbursement recommendations in healthcare systems with centralized HTA processes. Focus on the Polish HTA agency13
Direct diabetes-related healthcare expenditures in Slovenia: recent evolution and future projections based on population-level data13
A methodological guide for implementing and interpreting results of probabilistic analysis13
Cost-effectiveness analysis of tofacitinib for the treatment of moderate to severe rheumatoid arthritis: a systematic review and meta-analysis13
A projected cost-utility analysis of avacopan for the treatment of antineutrophil cytoplasmic antibody-associated vasculitis in Spain12
Burden of disease and costs of infections associated with cardiac implantable electronic devices12
Cost-effectiveness comparison of dalpiciclib and abemaciclib combined with an aromatase inhibitor as first-line treatment for HR+/HER2− advanced breast cancer11
The impact of under-investment on health in Southern and Central Eastern European Countries11
Consumption of antidepressants and economic austerity in Brazil11
Cost-effectiveness analysis of nivolumab-chemotherapy as first-line therapy for locally advanced/metastatic gastric cancer: a United States payer perspective11
Outcome measures for physical fatigue in individuals with multiple sclerosis: a systematic review10
Mapping of the health of the Nation Outcomes Scale (HoNOS) and Positive and Negative Symptom Scale (PANSS) to the EQ-5D-3L in psychosis patients using the PHAMOUS study9
The role of insurance policies in the drug pricing landscape9
Regulatory perspectives on post-market evidence generation schemes for high-risk medical devices: a systematic review9
Valuing quality of life for economic evaluations in cancer: navigating multiple methods9
International comparability of reference unit costs of education services: when harmonizing methodology is not enough (PECUNIA project)9
The impact of bone turnover marker on medication adherence and the health economics-related consequences9
Assessment of the properties of the EQ-5D-5L in patients with type 2 diabetes mellitus: a systematic review and meta-analysis8
Digital measures in epilepsy in low-resourced environments8
The economic burden of biologic disease-modifying antirheumatic drugs in rheumatoid arthritis patients in the United States8
Access to medicines, care, and services for multiple sclerosis patients in Central and Eastern European countries: a comparative analysis8
Cost-utility analysis of multiple sclerosis rehabilitation in Iran8
An update on the economic burden of type 2 diabetes mellitus in China7
Systematic reviews of machine learning in healthcare: a literature review7
Burden of illness among intermittent catheter users with non-neurogenic urinary retention in Denmark7
Pembrolizumab combined with chemotherapy versus placebo combined with chemotherapy for HER2-negative advanced gastric cancer in China: a cost-effectiveness analysis7
Cost–utility analysis of dupilumab compared with endoscopic sinus surgery in patients with chronic rhinosinusitis with nasal polyps. Evaluation in Colombia, a developing country7
Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric/gastroesophageal junction cancer in the Chinese healthcare system7
Adherence to oral anticoagulants in patients with non-valvular atrial fibrillation: the role of patients’ characteristics and out-of-pocket payments6
Value elements and methods of value-based pricing for drugs in Japan: a systematic review6
How relevant is the BMI for cost-of-illness studies in the 21st century?6
Impact of patient’s financial burden of COVID-19 treatment on antiviral prescription rates and clinical and economic outcomes6
Economic value of toripalimab plus axitinib as first-line treatment for advanced renal cell carcinoma in China: a model-based cost-effectiveness analysis6
Patients’ health related quality of life after massive weight loss reconstruction in the Netherlands6
The socioeconomic burden of cervical cancer and its implications for strategies required to achieve the WHO elimination targets6
Physician and patient adherence in hypertension trials: a point of view on an important issue to resolve6
Cost-effectiveness of daratumumab in combination with lenalidomide and dexamethasone for relapsed and/or refractory multiple myeloma6
Evaluation instruments for executive functions in children and adolescents: an update of a systematic review6
Prevalence and direct costs of potentially inappropriate prescriptions in France: a population-based study6
Estimation of the economic burden of atrial fibrillation-related stroke in Greece6
Precision medicine in Thoracic Oncology: understanding disparities to tackle inequities in access5
Mapping the World Health Organization Disability Assessment Scale 2.0 to the EQ-5D-5L in patients with mental disorders5
Healthcare costs, resource utilization, and productivity loss associated with colorectal cancer screening5
Transdisciplinary health economics for 2050: the challenge of preventing the adverse health effects of obesity, inequalities, and climate change5
Real-world analysis of the economic and therapeutic burden in advanced breast cancer patients in Italy5
The substantial costs to society associated with obesity – a Danish register-based study based on 2002-2018 data5
In-hospital economic burden of anastomotic leakage after colorectal anastomosis surgery: a real-world cost analysis in Italy5
Bridging the gap: enhancing medication adherence through research and innovation5
Tenecteplase in managing acute ischemic stroke: a long-term cost–utility analysis in Iran5
Methodological standards for comparative effectiveness research: considerations for evidentiary review for medicare drug price negotiation5
Considering potential solutions for limitations and challenges in the health economic evaluation of gene therapies5
Intravenous and subcutaneous vedolizumab for moderately to severely active ulcerative colitis in Iran: a model-based cost-effectiveness evaluation5
Developing the Lebanese health economic evaluation guideline5
Economic analysis of cerliponase alfa for treatment of late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2)5
Reimagining pharmacoeconomics in the age of artificial intelligence: opportunities, challenges, and future directions5
Cost-effectiveness of camrelizumab plus chemotherapy versus chemotherapy alone as first-line therapy in advanced or metastatic esophageal squamous cell carcinoma5
A retrospective observational analysis of the real-world care pathway of people with hereditary transthyretin amyloidosis with polyneuropathy in Italy5
Are quality-adjusted life years (QALYs) becoming more expensive? Evidence from economic evaluations of diabetic therapeutics5
Valuing prevention: lessons and recommendations from a Dutch expert committee5
Burden of disease of chronic pain in Ecuador5
The hidden burden of atopic dermatitis in central and Eastern European countries4
Secondary healthcare resource utilization and related costs associated with influenza-related hospital admissions in adult patients, England 2016 – 20204
Psychometric properties of outcome measures for freezing of gait in Parkinson’s disease: a systematic review and meta-analysis4
How do patients value features of biological medicine in rheumatoid arthritis? A discrete choice experiment4
The impact of comprehensive public hospital reform on economic burden of inpatients with chronic obstructive pulmonary disease: evidence from a pilot city in western China4
Determination of the economically justifiable price of cenobamate in the treatment of focal-onset seizures in adult patients with drug-resistant epilepsy in Spain4
Cost-effectiveness analysis of olaparib and niraparib as maintenance therapy for women with recurrent platinum-sensitive ovarian cancer4
Economic benefits of global Collaborative Health technology4
Imputing missing patient-level data and propensity score matching in cost-effectiveness analysis in Crohn's disease4
Use of machine learning to predict bladder cancer survival outcomes: a systematic literature review4
Cost-utility of dapagliflozin plus standard treatment compared to standard treatment for the management of heart failure with reduced ejection fraction in Colombia4
Value-based health care in Western countries: a scoping review on the implementation of patient-reported-outcomes sets for hospital-based interventions4
Health and economic impact of the correct diagnosis of transthyretin cardiac amyloidosis in Spain4
The Lebanese health economic evaluation guideline4
Work absenteeism, disability, and lost wages among patients with acute myeloid leukemia and their caregivers: a cohort study using US administrative claims and productivity data4
Changes in treatment pattern and costs in advanced hepatocellular carcinoma (HCC)4
Clinical and economic outcomes associated with intravenous albumin fluid use in the intensive care unit: a retrospective cohort study4
Trastuzumab deruxtecan versus chemotherapy treated in patients with HER2-positive metastatic breast cancer: a cost-effectiveness analysis based on the DESTINY-Breast02 trial4
A cost analysis of a simplified model for HCV screening and treatment at a tertiary hospital in Zimbabwe4
Economic evaluation of reproductive carrier screening for recessive genetic conditions: a systematic review4
Pharmaceutical innovativeness index: methodological approach for assessing the value of medicines – a case study of oncology drugs4
Analysis of patients’ access to reimbursed biotechnological medicines for multiple sclerosis in Bulgaria and Greece4
Using natural language processing to analyze unstructured patient-reported outcomes data derived from electronic health records for cancer populations: a systematic review4
Preferences of people with diabetes for diabetes care in Germany: a discrete choice experiment4
Economic burden of comorbidities among COPD Patients hospitalized for acute exacerbations: an analysis of a commercially insured population4
Perceptions of risk sharing agreements in South Korea from the viewpoints of key stakeholders: a convergent parallel mixed approach4
Budget impact analysis of transurethral water vapor therapy for treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia in the Spanish national healthcare system4
The economic impact of pharmacist intervention during pandemics4
Economic evaluation of rotavirus vaccination: an important step of the introduction to the national immunization program in Thailand4
Enhancing pharmacist intervention targeting based on patient clustering with unsupervised machine learning4
Cost-effectiveness of first-line sintilimab plus chemotherapy versus chemotherapy for advanced esophageal carcinoma in China3
Assessment of Quality of Life 8-Dimension (AQoL-8D): translation, validation, and application in two Dutch trials in patients with epilepsy and schizophrenia3
System dynamics simulation for evaluating implementation strategies of genomic sequencing: tutorial and conceptual model3
Improved medication adherence in COPD patients using tiotropium or tiotropium olodaterol with the HealthPrize digital behavior change program3
Evaluating reporting of patient-reported outcomes in peptic ulcer disease: a meta-epidemiological study of randomized controlled trials3
Cost-utility of sintilimab plus chemotherapy vs chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction cancer in China3
Correction3
Economic evaluation of ivabradine in treatment of patients with heart failure: a systematic review3
Design and testing of a health economic Markov model for treatment of anorexia nervosa3
Cost and health impact analysis of herpes zoster vaccination in Norway3
Barriers to digital endpoints in data collection in low and middle-income countries3
Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis3
Can artificial intelligence separate the wheat from the chaff in systematic reviews of health economic articles?3
Perspectives in prospective comparative economic evaluations: a systematic review3
The short-term impact of copayment reductions for government subsidised medicines in Australia3
Assessing the impact of kidney cancer-related premature mortality and productivity loss in Greece and Portugal3
Healthcare resource utilization and associated costs in patients with metastatic castration-resistant prostate cancer in Greece3
Implementing a Managed Entry Agreement Framework in Cyprus3
Cost-effectiveness of toripalimab plus chemotherapy versus chemotherapy as first-line treatment for advanced non-small cell lung cancer in China: a societal perspective3
Economic burden of cervical cancer and premalignant lesions associated with human papilloma virus: a societal perspective3
Lorlatinib as a first-line treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: Α cost-effectiveness analysis in Greece3
Normative data and socio-demographic determinants of the dermatology life quality index in a large online sample of the Hungarian population3
Access and pricing of medicines for patients with rare diseases in the European Union: an industry perspective3
Comparative efficacy of later-line therapies for metastatic colorectal cancer: a network meta-analysis of survival curves3
The impact of fibrodysplasia ossificans progressiva (FOP) on patients and their family members: results from an international burden of illness survey3
What are the costs of managing neck and low back pain in Brazil? Investigation of a ten-year period from the perspective of the Brazilian public health system3
Burden of disease of chronic pain in Colombia3
Public value judgments about the criteria for reimbursement of medicines in South Korea3
Patient-relevance of outcome measures in breast cancer clinical trials: a cross-sectional comparative analysis of patient preferences and trials conducted between 2014 and 20243
A roadmap for applying machine learning when working with privacy-sensitive data: predicting non-response to treatment for eating disorders3
Value assessment of new interventions for Alzheimer’s disease dementia in Japan based on literature review and group interview3
Capturing the holistic value of biosimilars in Europe – part 1: a historical perspective3
Costs for global guideline-based diagnosis of mucormycosis in patients with neutropenia, hematopoietic stem cell, or solid organ transplantation – a perspective of the German healthcare system3
Inebilizumab for neuromyelitis optica spectrum disorders in Italy: a budget impact model3
Systematic review of the impact of health care expenditure on health outcome measures: implications for cost-effectiveness thresholds3
Budget impact of low-dose computed tomography screening for lung cancer in Argentina3
How do hospital characteristics and ties relate to the uptake of second-generation biosimilars? A longitudinal analysis of Portuguese NHS hospitals, 2015–20213
0.08032488822937